Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy
- 17 July 2012
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 130 (5), 1123-1129.e2
- https://doi.org/10.1016/j.jaci.2012.05.039
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factorsJournal of Allergy and Clinical Immunology, 2012
- Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergyJournal of Allergy and Clinical Immunology, 2011
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenNew England Journal of Medicine, 2011
- A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergyJournal of Allergy and Clinical Immunology, 2011
- Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challengeJournal of Allergy and Clinical Immunology, 2009
- Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2006
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004
- Effect of Anti-IgE Therapy in Patients with Peanut AllergyNew England Journal of Medicine, 2003
- Expression and modulation of FcϵRIα and FcϵRIβ in human blood basophilsJournal of Allergy and Clinical Immunology, 2001
- Spontaneous Release of Histamine from Basophils and Histamine-Releasing Factor in Patients with Atopic Dermatitis and Food HypersensitivityNew England Journal of Medicine, 1989